New Research Confirms the Importance of Collecting Country-Specific Cost Data in the Treatment of Alzheimer’s Disease

Published Oct 21, 2019

Direct Medical Costs (Including Prescriptions) in Thailand Represent a
Markedly Higher Percentage of Total Costs Than in Other Countries

Lawrenceville, NJ, USA—October 21, 2019—Value in Health, the official journal of ISPOR—the professional society for health economics and outcomes research, announced today the publication of an analysis showing that direct medical costs are the major cost driver of Alzheimer’s disease care in Thailand, a finding distinct from other countries across the world. The report, “A Real-World Evidence Analysis of Associations Among Costs, Quality of Life, and Disease-Severity Indicators of Alzheimer’s Disease in Thailand,” was published in the October 2019 issue of Value in Health

Researchers collected real-world cost and health-related quality of life (HRQOL) data in Alzheimer’s disease patients in Thailand, then investigated their associations with multiple disease-severity indicators. Among community-dwelling patients, average annual total societal costs of Alzheimer’s disease care were $8014 per patient. Total costs of patients with severe stage ($9860) were almost twice as high as those of mild stage ($5524). Importantly, the major cost driver was direct medical costs, particularly those for Alzheimer’s disease prescriptions. The research also determined that increases in cognitive and functional status are significantly associated with decreases in total costs of Alzheimer’s disease care and improvement in patient’s HRQOL.

When comparing the cost of Alzheimer’s disease treatment in Thailand with that in other countries, the authors found substantive disparities. Direct medical costs, constituting 47.2% of the total costs in Thailand, represented a markedly higher percentage of total costs than in other studied countries. Notably, the costs incurred by Alzheimer’s disease prescriptions in Thailand were the largest part (39.8%) of direct medical costs.

“Our research was guided by the recognition that differences in cultural characteristics and healthcare settings can cause significant variations in Alzheimer’s disease cost estimates,” said author Nathorn Chaiyakunapruk, PharmD, PhD, Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA. “Therefore, it is important that each country has its own cost data to precisely discern the extent of impact that Alzheimer’s disease imposes on their economy. We found that direct medical costs were the major cost driver of Alzheimer’s disease care in Thailand, which is distinct from other countries across the world. Country-specific cost data are essential, because available data from other countries in the same region or income-country group may not be representative of all countries. Cost-effectiveness evidence is warranted to help governments curb the costliness of Alzheimer’s disease medications.”


ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Web: | LinkedIn: | Twitter: (@ISPORorg) | YouTube: | Facebook: | Instagram:

Value in Health (ISSN 1098-3015) is an international, indexed journal that publishes original research and health policy articles that advance the field of health economics and outcomes research to help healthcare leaders make evidence-based decisions. The journal’s 2018 impact factor score is 5.037. Value in Health is ranked 4th among 81 journals in health policy and services, 5th among 98 journals in healthcare sciences and services, and 11th among 363 journals in economics. Value in Health is a monthly publication that circulates to more than 10,000 readers around the world.
Web: | Twitter: (@ISPORjo

Explore Related HEOR by Topic

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now